Skip to main content

Next-generation assay provides a rapid and cost-effective solution to quantify IgG production in single cells.

Cambridge, UK, 04 June, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the launch of Cyto-Cellect®PLUS. In conjunction with the Company’s Cyto-Mine® platform, the new assay provides a streamlined method to measure antibody production in single cells by rapidly detecting secreted human IgG, enabling the identification and selection of cells with the highest productivity for more efficient cell line development.

Cyto-Cellect®PLUS is a robust and easy-to-use Fluorescence Resonance Energy Transfer (FRET) assay that enables researchers to quantify IgG productivity with high sensitivity. Expanding on Sphere Fluidics’ original Cyto-Cellect® Human IgGκ Detection Kit, Cyto-Cellect®PLUS now detects both the IgG κ and λ light chains to support a broader range of projects. The assay is fully compatible with existing Cyto-Mine® functionality, including single cell dispensing into 96-well and 384-well plates, allowing it to seamlessly integrate into customers’ existing cell line development workflows and conforms to relevant regulatory requirements by being animal-origin-free.

Cyto-Mine® is an automated platform which integrates single cell screening, sorting, dispensing, imaging, and clone verification in one bench-top system. Underpinned by the Company’s patented, microfluidic picodroplet technology, it can automatically screen up to 40 million cells in a matter of hours, compared with 10,000 typically achieved using multi-step manual techniques. This accelerated throughput is already widely recognized across a variety of research areas, including antibody discovery, cell line development, cell engineering and synthetic biology. The platform also facilitates rapid, high-throughput single cell manipulation and analysis across an expanding range of emerging research areas, including precision genome editing and cell therapy.

Richard Hammond, Chief Technology Officer, Sphere Fluidics, commented: “Building on the success of our original Cyto-Cellect® kit, we’re excited to bring this new assay to customers. Cyto-Cellect®PLUS also enables IgGλ detection; something that has previously been unavailable and introduces a unique solution to our customer offerings. This launch demonstrates ongoing innovation and expansion of our capabilities, in line with our plans to accelerate commercial roll out. By enabling researchers to quantify productivity at the single-cell level, we are working small, so they can think big.”

Maryam Ahmadi, Director of Cell and Molecular Biology, Sphere Fluidics, added: “Cyto-Cellect®PLUS leverages the technical expertise and dedication of our team to meet the evolving demands of our customers’ workflows. By facilitating the detection of both light chains of IgG, this assay builds on our original Cyto-Cellect® kit, providing a complete solution to enable researchers to identify and select cells with the highest productivity for downstream research. Ongoing research and development of new assays reflects our commitment to providing innovative solutions for our customers, empowering them to expand their research capabilities.”


For further information please contact:

Dr Claire Cox
Sphere Fluidics Ltd.
Tel: +44 (0)7365 209 441

Zyme Communications
Lily Jeffery
Tel: +44 (0)7891 477 378

About Sphere Fluidics

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed. 

Sphere Fluidics’ proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally. 

Sphere Fluidics is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors. 

For further information contact:

news icon

Stay ahead with Sphere Fluidics

Join our community of forward-thinking scientists and stay informed with the latest breakthroughs, product launches, and exclusive offers. By subscribing to our newsletter, you'll be the first to know about innovations that can transform your lab.

You may also like